Chemed Corporation $CHE Holdings Reduced by Smith Salley Wealth Management

Smith Salley Wealth Management lessened its stake in shares of Chemed Corporation (NYSE:CHE) by 17.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,570 shares of the company’s stock after selling 2,981 shares during the quarter. Smith Salley Wealth Management owned about 0.10% of Chemed worth $6,524,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Acadian Asset Management LLC boosted its position in shares of Chemed by 69.3% in the second quarter. Acadian Asset Management LLC now owns 250,722 shares of the company’s stock worth $122,056,000 after buying an additional 102,597 shares during the period. Boston Trust Walden Corp lifted its position in shares of Chemed by 0.4% during the 2nd quarter. Boston Trust Walden Corp now owns 247,434 shares of the company’s stock worth $120,483,000 after purchasing an additional 1,083 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Chemed by 160.9% in the second quarter. AQR Capital Management LLC now owns 201,041 shares of the company’s stock worth $97,893,000 after acquiring an additional 123,982 shares during the last quarter. Norges Bank bought a new stake in shares of Chemed in the second quarter valued at about $89,388,000. Finally, DekaBank Deutsche Girozentrale lifted its holdings in shares of Chemed by 0.4% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 155,267 shares of the company’s stock worth $75,604,000 after acquiring an additional 688 shares during the period. 95.85% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Bank of America reduced their price objective on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Royal Bank Of Canada decreased their price objective on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. Finally, Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and lifted their target price for the company from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $574.25.

Chemed Price Performance

CHE opened at $430.83 on Wednesday. The company has a market capitalization of $6.10 billion, a price-to-earnings ratio of 22.78, a P/E/G ratio of 2.43 and a beta of 0.46. The business’s 50-day moving average price is $435.11 and its two-hundred day moving average price is $452.34. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The firm had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. During the same period last year, the company earned $5.64 EPS. The company’s revenue was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. Sell-side analysts anticipate that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Monday, November 17th were issued a $0.60 dividend. The ex-dividend date was Monday, November 17th. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Chemed’s dividend payout ratio (DPR) is presently 12.69%.

Insider Buying and Selling at Chemed

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $437.55, for a total value of $875,100.00. Following the sale, the chief executive officer owned 94,197 shares of the company’s stock, valued at approximately $41,215,897.35. The trade was a 2.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.29% of the stock is owned by insiders.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.